Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.56 USD
+0.17 (0.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.56 USD
+0.17 (0.92%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $18.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Zacks News
Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TEVA) Outperforming Other Medical Stocks This Year?
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $11.25, moving -0.71% from the previous trading session.
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Novartis' sBLA for Ofatumumab Gets Extended Review From FDA
by Zacks Equity Research
The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Can Teva (TEVA) Return to Growth in This Year or Next?
by Zacks Equity Research
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
by Zacks Equity Research
Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.
Teva (TEVA) Q1 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Teva beats estimates for earnings and sales in first-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $10.84, marking a +1.12% move from the previous day.
Is a Beat in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Lilly (LLY) Q1 Earnings Beat, Coronavirus May Mar Profits
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both earnings and sales in the first quarter of 2020. However, the company warns that coronavirus-related uncertainty may hurt financial results in 2020 and beyond.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.54 in the latest trading session, marking a +0.85% move from the prior day.
Novartis Terminates Sale of Sandoz Dermatology Business
by Zacks Equity Research
Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
Amarin's Stock Plunges Following Unfavorable Patent Ruling
by Zacks Equity Research
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
COVID-19 Claiming Lives But Therapeutics Could Be on the Way
by Sejuti Banerjea
The WHO's Solidarity testing project could be good news for the world.
Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma
by Zacks Equity Research
Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.90, moving +0.77% from the previous trading session.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
by Zacks Equity Research
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.26, marking a +1.26% move from the previous day.
Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
by Ekta Bagri
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.